Brought to you by 
Achillion nets $41.7mm via RDO
31 Aug 2012
Executive Summary
Infectious disease-focused Achillion Pharmaceuticals Inc. has netted $41.7mm through the sale of 6.4mm common shares at $6.57 (market average) to funds managed by QVT Financial LP. The money will support ongoing development of its lead hepatitis C candidates sovaprevir (ACH1625; Phase II), ACH2684 (Phase I), and ACH3102 (Phase I).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Private Investment in Public Equity
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com